Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis (NCT07286058)
A Phase 3, Multicenter, Long-Term Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Either Biologic DMARD-NaΓ―ve or Biologic DMARD-Experienced, Including Those With Inadequate Response to Biologic DMARDs
π©Ί Plain-English Summary (8th-Grade Level)
Psoriatic arthritis (PsA) is a long-term inflammatory disease that affects the joints and skin. The purpose of this study is to check how safe zasocitinib is, how well it is tolerated and how well it works in adults with PsA over a longer period of time. Adults who completed the 1-year (52-week) treatment period in one of the parent studies (TAK-279-PsA-3001 \[NCT06671483\] or TAK-279-PsA-3002 \[NCT06671496\]) may be able to join this continuation study (also called long-term extension or LTE study). All participants in this continuation study, will receive zasocitinib (lower or higher dose), once a day (QD). Each participant can be in this study for approximately 2 years (108 weeks). This includes a treatment period of up to 2 years (104 weeks) and a 1-month (4-week) follow-up period to monitor a participant's health.
Who can join: Review the eligibility criteria below.
Location: First OC Dermatology Research Inc. β Fountain Valley, California
Age range: 18 Years
π§ͺ Interventions in This Study
π "Do I Qualify?" β 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria β
π All Participating Trial Locations (45 Sites)
Showing the first 25 of 45 sites.
- First OC Dermatology Research Inc. β Fountain Valley, California
- Purushotham & Akther Kotha MD β La Mesa, California
- Triwest Research Associates LLC β La Mesa, California
- The Cohen Medical Centers β Thousand Oaks, California
- Denver Arthritis Clinic - Lowry β Denver, Colorado
- Direct Helpers Research Center β Hialeah, Florida
- Sweet Hope Research Specialty, Inc, d/b/a Neoclinical Research β Hialeah, Florida
- IRIS Research and Development β Plantation, Florida
- Klein and Associates, M.D., P.A. β Hagerstown, Maryland
- Paramount Medical Research & Consulting, LLC β Middleburg Heights, Ohio
- West Tennessee Research Institute β Jackson, Tennessee
- Accurate Clinical Research β Baytown, Texas
- Novel Research LLC β Bellaire, Texas
- Novel Research | Abigail Neiman - Houston, TX β Houston, Texas
- Northwest Houston Arthritis Center β Houston, Texas
- West Texas Clinical Research β Lubbock, Texas
- Advanced Rheumatology of Houston β The Woodlands, Texas
- R.K. Will Pty Ltd β Victoria Park, Western Australia
- Peking University Third Hospital β Beijing, Beijing Municipality
- Peking Union Medical College Hospital β Beijing, Beijing Municipality
- Guangzhou First People's Hospital β Guangzhou, Guangdong
- Central South University - Xiangya School of Medicine - Zhuzhou Central Hospital β Zhuzhou, Hunan
- Linyi People's Hospital β Linyi Shi, Shandong
- First Hospital of Shanxi Medical University β Taiyuan, Shanxi
- MEDICAL Plus s.r.o. β UherskΓ© HradiΕ‘tΔ,
π Contact the Study Coordinator
Phone: (877) 825-3327
Email: medinfoUS@takeda.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
π° Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA Β§ 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Psoriatic Arthritis
- A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are NaΓ―ve to Biologic Disease-modifying Anti-rheumatic Drugs β Gilbert, Arizona
- Psoriatic Arthritis D2P Screening β Philadelphia, Pennsylvania
- Long Term Evaluation of Safety and Efficacy of Tildrakizumab in Patients With Psoriatic Arthritis β Dothan, Alabama
- Apremilast Pregnancy Exposure Registry β La Jolla, California
- Psorcast Mobile Study β Seattle, Washington
- A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy β Anniston, Alabama
Explore by condition: All Psoriatic Arthritis clinical trials
π‘ How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.